Wednesday, January 16, 2013

OTC Automotive Stock Trading Alert; MWW Automotive (OTCQB: MWWC) Continues Gains Following Financial Reporting

Point Roberts, WA - January 16, 2013 (Investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors, including automotive stocks, issues a trading alert for MWW Automotive Group (OTCQB: MWWC). The stock moved up 0.0002 or 66.67% in yesterday’s session on over 75 Million shares and continues its gains, trading up another 20% today on volume of over 73 Million as of 1:20 EST.
The company reported financial results for fiscal 2012 on the close yesterday.
http://finance.yahoo.com/news/mww-automotive-reports-financial-results-221900454.html
Investorideas.com Newswire About MWW Automotive Group (OTCQB: MWWC)
The MWW Automotive Group (MWWC) is headquartered in Howell, Michigan, with a "Class A" manufacturing and logistics facility in Baroda, Michigan for the production of high quality OE automotive and industrial products. MWW delivers its products and "Class A" painting, assembly and logistics services directly to major US and Foreign automobile manufacturers' Vehicle Processing Centers (VPC) and/or assembly lines in North America. MWW's industrial products are delivered directly to the industrial manufacturers for installation in their facilities. MWW provides substantial added value to the sale of vehicles and industrial products for leading international automobile and industrial manufacturers such as Toyota, BMW, Chevrolet, Hyundai, Kia Motors, MAZDA, GM, Ford, and their strategic partners ROUSH Performance and Polytec.

For more information please visit www.mwwautomotive.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; auto stocks, renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Research more automotive stocks at Investorideas.com
http://www.investorideas.com/AUTO/Stock_List.asp
Sign up for free stock news and trading alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com has been compensated for news release distribution and publishing on its affiliates and partners: equivalent of six thousand in 144 shares.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source Investorideas.com 800 665 0411

Mining Stocks Investor Alert: SilverCrest (TSX.V: SVL) (NYSE MKT: SVLC) Exceeds 2012 Production Market Guidance, Announces Q4 Results and 2013 Guidance

VANCOUVER, BRITISH COLUMBIA - January 16, 2013 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX.V:SVL) ( NYSE MKT: SVLC) (CW5.F) (the "Company") is pleased to announce full year and Q4 production figures for 2012 from its 100% owned Santa Elena Mine located in Sonora, Mexico and provide production and cost guidance for 2013.

2012 Operating Highlights for Santa Elena
  • Produced 579,609 ounces of silver in 2012, exceeding market guidance by 33% of original estimation of 435,000 ounces of silver.
  • Produced 33,004 ounces of gold in 2012, just below market guidance of 33,500 ounces.
  • Produced 2.37 million ounces of silver equivalent using a Ag:Au average ratio of 54.3:1.
  • In Q4 surpassed "One Million Ounces of Silver" produced project to date plus a quarterly record of 153,863 ounces silver.
  • Crusher throughput averaged 3,162 tonnes per day, 26% above the daily designed capacity of 2,500 tonnes per day.
  • Completed Phase II leach pad construction on schedule and on budget adding 2 years of capacity.
  • Installed new conveyor and stacker system for ore transport to the leach pad reducing operating costs.
  • Secured major long lead time items for construction of a new conventional 3,000 tpd CCD processing facility during 2013.
  • Underground decline development progressed to approximately 1,050 metres in length.
  • Completion of approximately 30,000 metres of drilling which;
    1. confirmed and detailed underground resources to be converted to reserves,
    2. discovered the new high grade "El Cholugo" gold and silver zone adjacent to the Main Mineralized Zone currently being mined and
    3. extended the Main Mineralized Zone more than 200 metres along strike and down plunge.
J. Scott Drever, President stated; "2012 was a very successful year for SilverCrest that marked our first full year in commercial production. Management congratulates our operating team for delivering on its commitments and meeting or exceeding our production targets. Santa Elena exceeded silver initial production guidance by 33% and produced 2.37 million silver equivalent ounces in 2012. We look forward to another exciting year at Santa Elena, remaining focused on continuing steady production, optimizing operations, and ensuring the expansion plan to double metal production in 2014 is kept on schedule and within budget."
During the fourth quarter of 2012, Santa Elena operations produced a record 153,863 silver ounces or 17% more than the same quarter in 2011. Silver production continues to set quarterly records due to improvement in recoveries and higher grade ore being loaded on the Phase II leach pad. Gold production of 7,831 ounces was consistent with budget but 18% below the same quarter in 2011. Open pit tonnes and grades continue to reconcile closely with the geological block model and mine plan. All aspects of operations continue to function well. The crushing circuit had an excellent fourth quarter with average throughput of 3,355 tonnes per day, 3% below the same quarter in 2011 and 34% above the daily design capacity of 2,500 tonnes per day.
Investorideas.com Newswire In 2012, virtually all operating parameters exceeded those of 2011 with the exception of the gold grade and gold ounces delivered to the pad. During the year the cut off grade was reduced from 0.38 gpt Au eq. to 0.20 gpt Au eq. (applies a 55:1 Ag:Au ratio, metallurgical recoveries, operating costs and current metal prices) which provided more reserve tonnes but with a lesser reported gold grade. In addition, much of the planned mining in 2012 was scheduled in a portion of the open pit which was of a lower grade when compared to those gold grades mined in 2011. Gold, along with silver grades are anticipated to increase in 2013.
2013 Operating Targets and Capital Expenditure Guidance
  • Produce 625,000 ounces of silver and 33,000 ounces of gold (2.4 million ounces of silver equivalent, Ag:Au 55:1) with consistent production levels expected each quarter.
  • Estimated cash cost of $8.50 per silver equivalent ounce (Ag:Au 55:1).
  • Major Capital Expenditures Estimates for Santa Elena Mine;
    • Expansion Capital - Mill facility: $53.2 million
    • Expansion Capital - U/G Mine Development: $ 7.8 million
    • Expansion Drilling and PFS $ 3.5 million
    • Sustaining Capital: $ 1.0 million
  • Estimated Exploration Expenditures;
    • La Joya - drilling and PEA: $ 6.5 million
    • La Joya - Property Acquisition Payment: $ 4.0 million
The Company is targeting 2013 year end for the completion of the new mill facility with commercial production expected in the first quarter of 2014. Exploration expenditures may be adjusted throughout the year depending on success.
The Qualified Person under National Instrument (NI 43-101) Standards of Disclosure for Mineral Projects for this News Release is N. Eric Fier, CPG, P.Eng, and Chief Operating Officer for SilverCrest Mines Inc., who has reviewed and approved its contents.
SilverCrest Mines Inc. (TSX-V: SVL; NYSE MKT: SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, Mexico. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Tuesday, January 15, 2013

OTC Automotive Stock Alert; MWW Automotive (OTCQB: MWWC) up 66%

Point Roberts, WA - January 15, 2013 (Investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors, including automotive stocks, issues a trading alert for MWW Automotive Group (OTCQB: MWWC). The stock is trading at 0.0005, up 0.0002 or 66.67% as of 2:30PM EST on over 63 Million shares.
Investorideas.com Newswire About MWW Automotive Group (OTCQB: MWWC)
The MWW Automotive Group (MWWC) is headquartered in Howell, Michigan, with a "Class A" manufacturing and logistics facility in Baroda, Michigan for the production of high quality OE automotive and industrial products. MWW delivers its products and "Class A" painting, assembly and logistics services directly to major US and Foreign automobile manufacturers' Vehicle Processing Centers (VPC) and/or assembly lines in North America. MWW's industrial products are delivered directly to the industrial manufacturers for installation in their facilities. MWW provides substantial added value to the sale of vehicles and industrial products for leading international automobile and industrial manufacturers such as Toyota, BMW, Chevrolet, Hyundai, Kia Motors, MAZDA, GM, Ford, and their strategic partners ROUSH Performance and Polytec.
For more information please visit www.mwwautomotive.com

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; auto stocks, renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Research more automotive stocks at Investorideas.com
http://www.investorideas.com/AUTO/Stock_List.asp
Sign up for free stock news and trading alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com has been compensated for news release distribution and publishing on its affiliates and partners: equivalent of six thousand in 144 shares.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source Investorideas.com 800 665 0411

OTC Biotech/ Pharma Stocks Alert: (OTCBB:SBFM), (OTCQB:ONCS), (OTCQB:XXII), (OTCQB:LJPC)

Point Roberts, WA - January 15, 2013 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert for investors following stocks in the small and microcap markets. Recent news from Sunshine Biopharma Inc. (OTCBB: SBFM), OncoSec Medical Inc. (OTCQB: ONCS), 22nd Century Group, Inc. (OTCQB/OTCBB: XXII) and (OTCQB: LJPC) has made headlines in yesterday's and today's trading session.

Sunshine Biopharma Inc. (OTCBB: SBFM) reported today that its parent company, Advanomics Corporation, has just filed in the United States a new patent application covering various manufacturing methodology and molecular aspects of Adva-27a. Advanomics intends to expand this new Adva-27a protection worldwide by filing appropriate international patent applications within the prescribed time limits from this initial filing. Advanomics has recently completed acquisition of the original Adva-27a worldwide patents filed in April 2007 from Institut National des Sciences Appliquees, a government research lab in France. If granted, this new patent filing will extend Adva-27a exclusivity by nearly six years, from April 2027 to January 2033.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
"Having an upgraded patent position is extremely important in the drug business", said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "Coverage of the new molecular aspects of Adva-27a and the approximately six additional years of protection factor significantly into the Company's financial equations", he added.
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, reported the company's upcoming milestones for 2013 at the Biotech Showcase conference held January 7-9 in San Francisco, CA.
OncoSec Medical Incorporated (ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics.
22nd Century Group, Inc. (OTCQB/OTCBB: XXII) reported that it closed a private placement on Friday, January 11, 2013 with an institutional investor. 22nd Century sold 2500 shares of its Series A convertible preferred stock and a 5-year warrant for an aggregate purchase price of $2.5 million. 22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding.
La Jolla Pharmaceutical Company (OTCQB: LJPC ) a company in the development of therapeutics that target galectin-3, announced that it has recently made two additions to its management team.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com including biotech stocks:
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at Investorideas.com biotech stock directory of TSX, OTC, NASDAQ and NYSE stocks :
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SBFM is an expired news publication and content client on Investorideas.com . Investorideas.com was previously compensated and is long SBFM shares. More info : http://www.investorideas.com/About/News/Clientspecifics.asp. Investorideas was not compensated for this release. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Sunwin Stevia Stevia (OTCQB: SUWN) Seeks Patents in China for its A3-99 production methodology; A3-99 extracts are among the highest quality stevioside extracts produced in the world

QUFU, CHINA - January 15, 2013 (Investorideas.com Newswire) China /stevia stocks news alert: Sunwin Stevia International, Inc. "Sunwin" (OTCQB: SUWN) one of the top global providers of high quality stevia extracts including Rebaudioside A 98, reports that its facilities are now capable of producing A3-99 stevia products. The addition of A3-99 to its commercial production capabilities is part of its previously announced stevioside expansion project.

A3-99 extracts are among the highest quality stevioside extracts produced in the world and are used in the pharmaceutical and food and beverage industries. Sunwin Stevia has completed testing for this production process making it one of a select few producers of A3-99 in China. Management expects to begin delivering shipments of the A3-99 to Zhejiang Huisong Pharmaceuticals, a pharmaceutical customer in China, in the fourth quarter of fiscal 2013 which begins in February 2013. Sunwin also intends to seek patents in China for its A3-99 production methodology.
"We are excited to add A3-99 to our commercial product offerings making Sunwin Stevia one of a select few suppliers capable of producing this extract on a large scale. Our recent facility upgrade has substantially increased our overall capabilities and we anticipate further additions to our production capabilities as we continue testing and trial production runs," commented Dongdong Lin, CEO of Sunwin Stevia. "We believe our technology is state of the art and we intend to seek a patent for our methodologies. We look forward to actively marketing our A3-99 stevia in China and eventually in the international markets in the coming quarters.”
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com
Safe Harbor Statement
Sunwin Stevia International, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our ability to return our revenues to historical levels, our dependence on continued market acceptance of our products, competition, our ability to control our raw material costs, risks associated with operating in China, and other risk factors impacting our company, some of which may be beyond our control. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2012.
Contact:
Dore Perler
U.S. Representative
954-232-5363
ir@sunwininternational.com
Published at Investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand per week for news publication, dissemination and profile on Investorideas.com, its affiliate news and email sites http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Note: An Emerging Strategy to Treat Metastatic Breast Cancer

SAN DIEGO - January 15, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Investorideas.com Newswire
In 2012, researchers published the discovery that small particles known as exosomes are secreted by tumors to seed the creation and spread of cancer metastases. These same tumor-secreted exosomes have also been implicated in death of immune cells necessary to combat cancer and they facilitate the ability of tumors to create their own blood supply for survival. The Aethlon Hemopurifier� is the first therapeutic strategy to address these vital targets in cancer care. Based on our early research in the field, we have issued patent protection that provides an opportunity to establish a dominant position within the marketplace. In this regard, we envision the elimination of tumor-secreted exosomes through Hemopurifier� therapy will optimize the performance of cancer therapies and augment the immune system's ability to combat cancer. Based on evidence that our Hemopurifier� captures exosomes underlying breast cancer, I am pleased to provide you with the following review authored by Dr. Annette Marleau, our Director of Tumor Immunology.
Current Perspectives on Breast Cancer Exosomes
Breast cancer represents a challenging clinical scenario that exhibits heterogeneous molecular types and enormous diversity of malignant behavior of tumors between patients. As the second most common cancer afflicting women in the United States, it is estimated that 1 in 8 women will be diagnosed with invasive breast cancer in their lifetime (1). Significant improvements in disease-free survival have been achieved; however, there is still a need to address the aggressive and metastatic forms of breast cancer.
Advances in the understanding of breast cancer pathogenesis at a molecular level have pointed toward central roles for exosomes, nano-vesicles released in abundance by cancer cells. Exosomes are packed with proteins and genetic material from the tumor, and act as cellular messengers that distribute these malignant factors systemically to target cells, including cancer cells as well as healthy cells. Recently, the dissemination of pro-cancer cargo by exosomes is has been appreciated as promoting several critical aspects of cancer pathogenesis, including signaling for tumor growth, metastasis, angiogenesis, and resistance to chemo- and immunotherapeutic agents. These scientific discoveries, some of which are discussed below, have been accompanied by a growing interest in means for targeting exosomes therapeutically.
Recent studies have identified several mechanisms underlying the secretion of breast cancer exosomes and their uptake by target cells. In the breast tumor microenvironment, hypoxia is a pathological state of oxygen deprivation that affects the expression of genes required for many critical aspects of cancer progression. A study by Dr. Jonathan Gleadle's laboratory in the journal BMC Cancer demonstrated that hypoxia stimulates exosome secretion by breast cancer cells (2), which can serve as a means for distributing a supply of cancer-promoting signals for the tumor mass. These investigations and many others also point toward exosomes as biomarkers for predicting the aggressiveness of a tumor.
Adding to the understanding of the physiological triggers of exosome secretion, Dr. Josiah Ochieng's group reported in PLoS One that exosomes are secreted in response to detachment of breast cancer cells from extracellular matrices (3). In turn, the secreted exosomes concentrate on the surfaces of breast cancer cells to facilitate their re-adhesion to surfaces. This study implicates cancer-secreted exosomes as having crucial roles in tissue invasion by metastasizing breast cancer cells. Aberrant glycosylation is a hallmark of cancer that promotes adhesiveness of cancer cells to one another and to extracellular matrices, endowing them with invasive and metastatic phenotypes. Indeed, tumor-secreted exosomes also display highly glycosylated surface structures (4), which could serve as binding targets of lectin affinity capture agents for pulling nanovesicles out of the circulatory system.
Recent studies have also provided considerable insight into the impact of breast cancer exosomes as vehicles for spreading oncogenic signals to diverse target cells. A pivotal publication in PNAS by Dr. Richard Cerione's group at Cornell University showed that the transfer of cargo by cancer exosomes is involved in cellular transformation, whereby healthy cells acquired the growth characteristics of tumor cells (5). Along these same lines is the recent publication in PLoS One, authored by Drs. Chang Lau and David Wong at UCLA, where breast cancer exosomes interacted with salivary gland cells, as evidenced by changes in the protein and genetic composition of exosomes secreted by the target cells(6). This report provides mechanistic insight as to how tumors are capable of communicating with target cells at distant sites via secretion of exosomes, making a therapeutic strategy for systemic removal of exosomes an attractive possibility for slowing cancer progression.
Significantly, there is also evidence that breast cancer exosomes might exert a direct role in resistance of tumors to therapeutic agents. In a paper by Dr. Serenella Pupa and colleagues published in the Journal of Cellular Physiology, exosomes from breast cancer cells that over-expressed the HER2 oncoprotein also displayed surface HER2, which bound to and sequestered the therapeutic antibody Herceptin in vitro (7). It was suggested that this decoy effect of cancer exosomes could lower the therapeutic benefits of immunotherapeutic agents, particularly in patients with advanced cancer where the exosome burden is expected to be high. On this basis, a strategy aimed at alleviating the exosome load might prove to be a promising adjunct therapy to improve the benefits of standard of care breast cancer treatments.
References
(1) http://www.breastcancer.org/symptoms/understand_bc/statistics
(2) King HW, Michael MZ and Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012; 12:421.
(3) Koumangoye RB, Sakwe AM, Goodwin JS, Patel T, Ocheing J. Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS One 2011; 6(9)e24234.
(4) Batista BS, Eng WS, Pilobello KT, Hendricks-Munoz KD, Mahal LK. Identification of a conserved glycan signature for microvesicles.J Proteome Res. 2011 Oct 7;10(10): 4624-33.
(5) Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL, Holowka DA, Cerione RA. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. ProcNatlAcadSci U S A. 2011 Mar 22; 108(12):4852-7.
(6) Lau CS, Wong DT. Breast cancer exosome-like microvesicles and salivary gland cells interplay alters salivary gland cell-derived exosome-like microvesicles in vitro. PLoS One. 2012; 7(3):e33037.
(7) Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012 Feb; 227(2):658-67.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock Breaking News; PARENT COMPANY OF SUNSHINE BIOPHARMA (OTCBB:SBFM) , FILES NEW PATENT APPLICATION FOR ITS MULTIDRUG RESISTANCE Adva-27a ANTICANCER COMPOUND

Montreal, Quebec, Canada - January 15, 2013 (Investorideas.com Newswire) Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCBB: SBFM), is pleased to announce that it has just filed in the United States a new patent application covering various manufacturing methodology and molecular aspects of Adva-27a. Advanomics intends to expand this new Adva-27a protection worldwide by filing appropriate international patent applications within the prescribed time limits from this initial filing. Advanomics has recently completed acquisition of the original Adva-27a worldwide patents filed in April 2007 from Institut National des Sciences Appliquees, a government research lab in France. If granted, this new patent filing will extend Adva-27a exclusivity by nearly six years, from April 2027 to January 2033.

Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
"Having an upgraded patent position is extremely important in the drug business", said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "Coverage of the new molecular aspects of Adva-27a and the approximately six additional years of protection factor significantly into the Company's financial equations", he added.
About Sunshine Biopharma Inc. (OTCBB:SBFM)
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a.
About Advanomics Corporation
Advanomics Corporation is a privately held Canadian company focused on the research and development of treatments for cancer and other human diseases. Advanomics is conducting research and development in the area of Carbon-Difluoride Chemistry to generate novel anticancer compounds and in the area of RNA Technology for deciphering genomic information and rapid identification of disease related molecular targets for therapeutic intervention.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at Investorideas.com newswire
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Sign up for the free investor news and stock alerts at Investorideas.com including biotech stocks:
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at Investorideas.com biotech stock directory of TSX, OTC, NASDAQ and NYSE stocks :
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SBFM is an expired news publication and content client on Investorideas.com . Investorideas.com was previously compensated and is long SBFM shares. More info : http://www.investorideas.com/About/News/Clientspecifics.asp. Investorideas was not compensated for this release.BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Monday, January 14, 2013

Stevia Stocks Breaking News; Sunwin Stevia (OTCQB:SUWN) Facility Receives AIB International Food Safety Certification

QUFU, CHINA - January 14, 2013 (Investorideas.com Newswire) Sunwin Stevia International, Inc. "Sunwin" (OTCQB: SUWN) one of the top global providers of high quality stevia extracts including Rebaudioside A 98, announced today that its production facility has received recognition of accomplishment for fulfilling the requirements of AIB International's consolidated standards for food safety.

AIB International provides a comprehensive list of audits and inspections, including their globally-recognized GMP Inspection, custom audits, and certifications under the Global Food Safety Initiative. AIB International audits are backed by more than 60 years of experience in the field for food manufacturing, beverages, ingredients and packaging. AIB International's services are used by many of the world's largest food manufacturers, distributors and food service operators. AIB International conducts audits in more than 120 countries covering producers ranging in size from multinationals to small, independent producers. AIB International conducted their inspection of Sunwin Stevia's facility in December 2012.
"We are pleased to have fulfilled the rigorous standards established by AIB for food safety. AIB is widely recognized as the leader in the industry for these types of inspections and audits," commented Dongdong Lin, CEO of Sunwin Stevia. "Our company and all of its employees have always had a commitment to quality and cleanliness during our production process, and now more than ever, our customers can be assured of Sunwin Stevia's commitment to food safety."
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com
Safe Harbor Statement
Sunwin Stevia International, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our ability to return our revenues to historical levels, our dependence on continued market acceptance of our products, competition, our ability to control our raw material costs, risks associated with operating in China, and other risk factors impacting our company, some of which may be beyond our control. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2012.
Contact:

Dore Perler
U.S. Representative
954-232-5363
ir@sunwininternational.com
Published at Investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand per week for news publication, dissemination and profile on Investorideas.com, its affiliate news and email sites http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Mining Stock News: SilverCrest (TSX.V: SVL) (NYSE MKT: SVLC) Expands Santa Elena Deposit; More High Grade Intercepts 13m @ 1.6 gpt Au and 324.8 gpt Ag Including 1m @ 5.1 Au and 2,840 gpt Ag

VANCOUVER, BRITISH COLUMBIA - January 14, 2013 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX.V:SVL) ( NYSE MKT: SVLC) (CW5.F) (the "Company") is pleased to announce results of further drilling at the Santa Elena Mine in Sonora, Mexico. Ninety four holes of a planned 100 holes have been completed to help re-categorize Indicated and Inferred Resources to Probable Reserves and expand current underground Resources (see attached Figure - http://media3.marketwire.com/docs/svl114-F1.jpg). This drill program continues to be extremely successful with several recent holes identifying multiple bonanza grade intercepts and the new El Cholugo high grade gold and silver zone. All holes included in this program will assist with Resource confirmation and reclassification to be included in the upcoming Pre-Feasibility Study for the Santa Elena Expansion Project.

J. Scott Drever, President stated; "We are extremely encouraged with the high grade silver intercepts that we are encountering and the fact that four of the high grade results are just on or well beyond our current resource boundary. Gold values and interval widths are also substantial which bodes well for the addition of resources in our upcoming Resource and Reserve revisions."
In this reported series, core holes SE-12-73 and 110 have intercepted further Bonanza grades of gold, greater than 34 gpt Au and/or silver, greater than 1,000 gpt Ag, ranging from 1.0 metre @ 4.47 gpt Au and 1,465 gpt Ag to 1.0 metres @ 5.07 gpt Au and 2,840 gpt Ag (see tables below). Results from Bonanza grade hole SE-12-62 were partially announced on Jan. 7, 2013 with a final intercept of 1.7 metre @ 42.59 gpt Au and 1,460 gpt Ag within 5.2 metres @ 15.34 gpt Au and 546.2 gpt Ag.
Holes SE-12-72, 73, 74, and 111 have intercepted an extension of strong mineralization along the Main Mineralized Trend to the east and at depth (see attached Figure - http://media3.marketwire.com/docs/svl114-F1.jpg). These intercepts are up to 200 metres beyond the boundary of current Resource estimates. This Expansion Area is currently approximately 300 metres long by 150 metres high by 5 to 13 metres thick and open to the east and at depth. These new intercepts will be included in the upcoming revised underground Resources and Reserves. Further drilling is underway to help delineate this area of expansion.
Assay values in this series of holes range from 0.7 gpt to 42.6 gpt gold and 51.1 gpt to 2,840.0 gpt silver. Mineralized intervals range from 2.8 metres to 28.2 metres. All mineralized drill intercepts are near true thicknesses. The most significant assay results in this series of holes are shown in the following tables;
Investorideas.com Newswire All sample analyses were completed by ALS Chemex in Hermosillo, Mexico and North Vancouver, BC.
Silver assays for Hole SE-12-62 pending in the news release dated January 7, 2012 are presented above. Hole SE-12-112 is absent in the above sequence as it is currently being drilled.
Approximately 33,000 metres of drilling have been completed to date in the program to assist with converting underground Resources to Reserves and expand total Resources. Results for the next series of holes will be released once compilation of results is complete. Three drills are currently on site to complete the in-fill program in early February, 2013. Further expansion drilling will be completed in Q1 2013. Revised Santa Elena Resources and Reserves are expected in Q1 2013 with subsequent reporting of the results of Pre-Feasibility Study for the Expansion Plan.
The Qualified Person under National Instrument (NI 43-101) Standards of Disclosure for Mineral Projects for this News Release is N. Eric Fier, CPG, P.Eng, and Chief Operating Officer for SilverCrest Mines Inc., who has reviewed and approved its contents.
SilverCrest Mines Inc. (TSX-V: SVL; NYSE MKT: SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, Mexico. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Thursday, December 27, 2012

Stevia and the Top Trends in Food and Beverage for 2013

Point Roberts, WA - December 27, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors issues a snapshot for stevia and its markets and opportunities and related stocks/agriculture stock Sunwin Stevia International, Inc. (OTCQB: SUWN), moving into 2013 and beyond . The industry is ramping up for new food and beverage products using stevia and new global markets opening up.

The 5th World Conference on Stevia: Stevia Tasteful 2013 - Food & Beverages Formulation: The Subtle Balance will be held in Paris, France on May 17, 2013. According to the WSO conference, "Stevia is currently considered as the "green gold", as natural sweetener used to reduce sugar and synthetic sweeteners as aspartame or sucralose. Moreover, Stevia as a natural and antioxidant ingredient can be used for the prevention of chronic diseases such as obesity, diabetes, cancer, and cardiovascular diseases."
Sunwin Stevia International, Inc. (OTCQB: SUWN) recently reported it " expects sales and operating income to improve in fiscal 2014 which begins on May 1, 2013 as worldwide demand for stevia is forecasted to rise and supply chain pricing pressures begin to ease. Sunwin Stevia sees fiscal 2014 revenue reaching $18 million in annual sales with $2 million in net operating income."
According to a recent article in SeekingAlpha.com on stevia stocks, "Sunwin began its expansion project in April anticipating an improvement in demand for stevia as a healthy low calorie sweetener and is now poised to capitalize on the industry's upward trend. With Canada's approval of stevia, it becomes apparent that the company was correct as stevia continues to grow in worldwide acceptance. Sunwin's new stevioside extraction line uses a state-of-the-art crystallization process that substantially reduces the production time while increasing product yield leading to a substantial reduction in overall processing costs as utilization rates increase. Sunwin has begun trial production of its new lines and anticipates its added production capabilities to be fully operational in the first quarter of 2013.
In August Sunwin entered into a worldwide stevia distribution agreement with WILD Flavors, giving WILD a non-exclusive worldwide right as a distributor to market and resell all Sunwin stevia products. Sunwin is also developing 6 new formulations in conjunction with WILD with the goal of penetrating the $10.3 billion Chinese bakery market by marketing to manufacturers to develop private label products - a move that the company sees will bolster its domestic production base in China.
Sunwin, with a market cap of $45.1 million, has had an impressive 3-month run, up 30% to $0.27 per share, but still off its 52-week high of $0.35 per share. In the past week of trading, its volume has risen to an average of 41,000 shares traded daily. I like the aggressiveness of Sunwin, and its timing appears to be spot on, especially with Canada's announcement last week. Given the continued expansion of stevia globally, Sunwin may well be one of those small companies that may benefit shareholders with impressive stock gains if its success continues." http://seekingalpha.com/article/1056111-companies-gear-up-as-health-canada-approves-stevia-as-additive-for-food-and-beverage-use?source=yahoo
Innova Market Insights' ongoing analysis of trends and developments in new product activity has resulted in its identification of 10 key emerging trends likely to impact the food and drinks market through 2013 and beyond. Stevia plays a big role in two of the top ten trends of replacing sugar:
4. Just Say "No." Free-from claims are becoming increasingly prevalent. Gluten-free is now relatively mainstream, with lactose-free set to follow suit as awareness of problems associated with nutrient intolerance rises and technological advances improve the quality and availability of a whole range of products. "No" products also encompass meat-free lines, with technology allowing the development of innovative vegetarian foods, as well as fat-, sugar- and salt-free alternatives.
7. Beating the Sugar Demon
"As rising levels of obesity and diabetes continue to dominate headlines, there has never been so much emphasis on reducing our caloric intake as well as consuming healthier foods and beverages," commented Zenith Senior Market Analyst Anya Hembrough. "After persistent efforts by key producers, legislators worldwide are finally giving the green light to this new zero-calorie sweetener".
The International Stevia Council (ISC) recently commented on Health Canada's approval saying it was "a very positive step as Canada joins other major markets around the world that have approved steviol glycosides use. In markets like Indonesia and South Africa stevia was approved recently. Approval is also on the way in India and Thailand and the ISC welcomes these developments."
Euromonitor forecasts that stevia will have an annual growth rate of 23% globally over 2011-2016, in volume terms.
About. Sunwin Stevia International, Inc. (OTCQB: SUWN).
Sunwin Stevia International, Inc. (OTCQB: SUWN) engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin Stevia has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin Stevia, please visit http://www.sunwininternational.com
Research more Agriculture stocks at Investorideas.com
http://www.investorideas.com/MSS/Arg_Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand per week for news publication, dissemination and profile on Invesotrideas.com , its affiliate news and email sites http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com